Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin Therapy

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943

Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848

Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes

Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

Sever, P., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M. J., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,790

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755

Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease

LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378

High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better

Grundy, S. M., Stone, N. J., Blumenthal, R. S., Braun, L. T., Heidenreich, P. A., Lloyd-Jones, D., Orringer, C. E., Saseen, J. J., Smith, S. C., Sperling, L. S., et al. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.02.032 · Cited by 20

Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: Economic analysis of the aggressive lipid-lowering initiation abates new cardiac events (ALLIANCE) study

Mullins, C. D., Rattinger, G. B., Kuznik, A., & Koren, M. J. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.12.007 · Cited by 20

Do Persons with Diabetes Benefit from Combination Statin and Fibrate Therapy?

Rosenblit, P. D. (2012) · Current Cardiology Reports · doi:10.1007/s11886-011-0237-7 · Cited by 20

Low-Dose Rosuvastatin Improves Arterial Stiffness in High-Risk Japanese Patients With Dyslipdemia in a Primary Prevention Group - A Comparison With Fluvastatin -

Hongo, M., Kumazaki, S., Izawa, A., Hidaka, H., Tomita, T., Yazaki, Y., Kinoshita, O., & Ikeda, U. (2011) · Circulation Journal · doi:10.1253/circj.cj-11-0497 · Cited by 20

Association of small dense lowdensity lipoprotein cholesterol in type 2 diabetics with coronary artery disease

Ning, H., Huang, Y.-C., Chang, P.-Y., & Hwang, J. (2014) · Biomedical Journal · doi:10.4103/2319-4170.132883 · Cited by 20

The role of statins in the treatment of the metabolic syndrome

Ott, C., & Schmieder, R. E. (2009) · Current Hypertension Reports · doi:10.1007/s11906-009-0025-6 · Cited by 20

Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?

Ara, R., Pandor, A., Stevens, J., Rafia, R., Ward, S. E., Rees, A., Durrington, P. N., Reynolds, T., Wierzbicki, A. S., & Stevenson, M. (2011) · European Journal of Preventive Cardiology · doi:10.1177/1741826711406616 · Cited by 19

An overview on nanoplatforms for statins delivery: Perspectives for safe and effective therapy

Etemad, L., Salmasi, Z., Moosavian Kalat, S. A., Moshiri, M., Zamanian, J., Kesharwani, P., & Sahebkar, A. (2023) · Environmental Research · doi:10.1016/j.envres.2023.116572 · Cited by 18

Guía de práctica clínica sobre revascularización miocárdica

Wijns, W. C., Kolh, P. H., Danchin, N., Mario, C. D., Falk, V., Folliguet, T. A., Garg, S., Huber, K., James, S. K., Knuuti, J. M., et al. (2010) · Revista Española de Cardiología · doi:10.1016/s0300-8932(10)70277-3 · Cited by 17

Not Getting to Goal: The Clinical Costs of Noncompliance

Ansell, B. J. (2008) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2008.14.s6-b.9 · Cited by 18

The impact of statin use on sepsis mortality

Li, M., Noordam, R., Trompet, S., Winter, E. M., Jukema, J. W., Arbous, M. S., Rensen, P. C. N., & Kooijman, S. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.07.006 · Cited by 17

Cardiovascular risk factors and recommended lipid goals attainment among patients referred in a tertiary care lipid clinic

Pirro, M., Giorno, R. D., Lupattelli, G., Mannarino, M. R., Roscini, A. R., Covelli, D., Schillaci, G., Pasqualini, L., Bagaglia, F., Siepi, D., et al. (2011) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2011.04.007 · Cited by 17

Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes

Rydén, L., estable, G. D. T. D. L. S. E. D. C. S. D. Y. T. D. L. C. I., Grant, P. J., Anker, S. D., Berne, C., Cosentino, F., Danchin, N., Deaton, C., Escaned, J., Hammes, H. P., et al. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2013.10.015 · Cited by 20

Exploring the gap between National Cholesterol Education Program guidelines and clinical practice in secondary care: results of a cross-sectional study involving over 10 000 patients followed in different specialty settings across Italy

Rapezzi, C., Biagini, E., Bellis, P., Cafiero, M., Velussi, M., Ceriello, A., Cooke, R. M. T., & Schweiger, C. (2008) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e3282f56513 · Cited by 17

Praluent (Alirocumab): First PCSK9 Inhibitor Approved by the FDA for Hypercholesterolemia.

Raedler, L. A. (2016) · Europe PMC (PubMed Central) · Cited by 17

Role of Lipid-Lowering Therapy in Low-Density Lipoprotein Cholesterol Goal Attainment: Focus on Patients With Acute Coronary Syndrome

Wang, Q., & Liang, C. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000914 · Cited by 17

Correlation of compliance to statin therapy with lipid profile and serum HMGCoA reductase levels in dyslipidemic patients

Grover, A., Rehan, H. S., Gupta, L. K., & Yadav, M. (2016) · Indian Heart Journal · doi:10.1016/j.ihj.2016.07.007 · Cited by 17

Management standards for stable coronary artery disease in India

Mishra, S., Ray, S., Dalal, J. J., Sawhney, J. P. S., Ramakrishnan, S., Nair, T., Iyengar, S. S., & Bahl, V. K. (2016) · Indian Heart Journal · doi:10.1016/j.ihj.2016.11.320 · Cited by 17

Cardioprotective repair through stem cell-based cardiopoiesis

Behfar, A., & Terzic, A. (2007) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00713.2007 · Cited by 17

Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?

Fabbri, G., & Maggioni, A. P. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0025-6 · Cited by 19

Development of a Risk‐Screening Tool for Cancer Survivors to Participate in Unsupervised Moderate‐ to Vigorous‐Intensity Exercise: Results From a Survey Study

Brown, J. C., Ko, E. M., & Schmitz, K. H. (2015) · PM&R · doi:10.1016/j.pmrj.2014.09.003 · Cited by 16

Triglycerides and Cardiovascular Outcomes—Can We REDUCE-IT ?

Pradhan, A. K., Bhandari, M., Vishwakarma, P., & Sethi, R. (2020) · International Journal of Angiology · doi:10.1055/s-0040-1701639 · Cited by 18

Management of Dyslipidemia in Women and Men with Coronary Heart Disease: Results from POLASPIRE Study

Setny, M., Jankowski, P., Krzykwa, A., Kamiński, K. A., Gąsior, Z., Haberka, M., Czarnecka, D., Pająk, A., Kozieł, P., Szóstak-Janiak, K., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122594 · Cited by 16

Statins and Cardiomyocyte Metabolism, Friend or Foe?

Somers, T., Siddiqi, S., Morshuis, W. J., Rüssel, F. G. M., & Schirris, T. J. J. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10100417 · Cited by 19

Comparative effectiveness of moderate-intensity statin with ezetimibe therapy versus high-intensity statin monotherapy in patients with acute coronary syndrome: a nationwide cohort study

Jang, J., Kim, S., Cho, J., Chun, S., You, S. C., & Kim, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-51310-5 · Cited by 18

Importance of Intensive Lipid Lowering in Acute Coronary Syndrome and Percutaneous Coronary Intervention

Kumar, A., & Cannon, C. P. (2007) · Journal of Interventional Cardiology · doi:10.1111/j.1540-8183.2007.00298.x · Cited by 16

Impact of Ezetimibe Coadministered With Statins on Cardiovascular Events Following Acute Coronary Syndrome: A 3-Year Population-Based Retrospective Cohort Study in Taiwan

Lin, C.-F., Gau, C., Wu, F. L., Hsiao, F., Bai, C., & Shen, L. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.08.002 · Cited by 16

Lipid-lowering effects of ezetimibe and simvastatin in combination

Ijioma, N., & Robinson, J. G. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.179 · Cited by 16

Rationale and Design of the PROSPECTIVE Trial: Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Prior Coronary Heart Disease

Yamashita, S., Masuda, D., Ohama, T., Arai, H., Bujo, H., Kagimura, T., Kita, T., Matsuzaki, M., Saitō, Y., Fukushima, M., et al. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.32813 · Cited by 16

Lipid-lowering therapy: Guidelines to precision medicine

Su, X., Cheng, Y., & Chang, D. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.12.019 · Cited by 15

Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non–HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein

Davidson, M. H., Abate, N. I., Ballantyne, C. M., Catapano, A. L., Xu, X., Lin, J., Rosenberg, E., & Tershakovec, A. M. (2008) · Journal of clinical lipidology · doi:10.1016/j.jacl.2008.10.003 · Cited by 16

Incidence and prognosis of angina pectoris in South Asians and Whites: 18 years of follow-up over seven phases in the Whitehall-II prospective cohort study

Zaman, M., Shipley, M. J., Stafford, M., Brunner, E. J., Timmis, A., Marmot, M. G., & Hemingway, H. (2010) · Journal of Public Health · doi:10.1093/pubmed/fdq093 · Cited by 16

Only a minority of patients referred for elective coronary artery bypass surgery have risk factors diagnosed and treated according to established guidelines

Anderson, R. E., Brismar, K., & Ivert, T. (2007) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2007.028 · Cited by 16

Patterns of statin prescription in acute myocardial infarction

Ferrières, J., Bataille, V., Leclercq, F., Geslin, P., Ruidavets, J., Grollier, G., Bernard, P., Cambou, J., Simon, T., & Danchin, N. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.09.031 · Cited by 16

The efficacy of intensive lipid-lowering therapies on the reduction of LDLc and of major cardiovascular events

Cordero, A., Olmo, R. F., Badimón, L., Santos‐Gallego, C. G., Castellano, J. M., Fácila, L., Rodríguez‐Mañero, M., Bonanad, C., Vilahur, G., Escribano, D., et al. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.08.006 · Cited by 16

Diabetic dyslipidaemia in Asian populations in the Western Pacific Region: What we know and don’t know

Chan, J. C. N., Chan, S. P., Deerochanawong, C., Go, R. T., Lee, K., Ronald, C. W., Pan, C., Sheu, W. H., & Barter, P. J. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.05.034 · Cited by 15

Lipid‐Altering Efficacy of Ezetimibe/Simvastatin 10/20 mg Compared to Rosuvastatin 10 mg in High‐Risk Patients with and without Type 2 Diabetes Mellitus Inadequately Controlled Despite Prior Statin Monotherapy

Vaverková, H., Farnier, M., Averna, M. R., Missault, L. H., Viigimaa, M., Dong, Q., Shah, A. K., Johnson‐Levonas, A. O., & Brudi, P. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00181.x · Cited by 15

Full-dose atorvastatin versus conventional medical therapy after non-ST-elevation acute myocardial infarction in patients with advanced non-revascularisable coronary artery disease

Colivicchi, F., Marco Tubaro, U., Mocini, D., Ebert, A. G., Strano, S., Melina, G., Uguccioni, M., & Santini, M. (2010) · Current Medical Research and Opinion · doi:10.1185/03007991003751496 · Cited by 15

Secondary prevention after CABG: do new agents change the paradigm?

Paquin, A., Poirier, P., Beaudoin, J., & Piché, M. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000783 · Cited by 15

Ranolazine in patients with angina and coronary artery disease

Scirica, B. M., & Morrow, D. A. (2007) · Current Cardiology Reports · doi:10.1007/bf02938375 · Cited by 15

Reducing the Residual Risk of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Therapy With Combination Therapy

Polonsky, T. S., & Davidson, M. H. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.051 · Cited by 15

Appropriateness of Dyslipidemia Management Strategies in Post-Acute Coronary Syndrome: A 2023 Update

Lucà, F., Oliva, F. G., Rao, C. M., Abrignani, M. G., Amico, A. F., Fusco, S. A. D., Caretta, G., Matteo, I. D., Nora, C. D., Pilleri, A., et al. (2023) · Metabolites · doi:10.3390/metabo13080916 · Cited by 17

Comparing effectiveness of high-dose Atorvastatin and Rosuvastatin among patients undergone Percutaneous Coronary Interventions: A non-concurrent cohort study in India

Roy, D., Mahapatra, T., Manna, K., Kar, A., Rana, M. S., Roy, A., Bose, P. K., Banerjee, B., Paul, S., & Chakraborty, S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233230 · Cited by 14

Recent trials of lipid lowering

Ray, K. K., Cannon, C. P., & Braunwald, E. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01425.x · Cited by 16

Lipid lowering goals: back to nature?

Hochholzer, W., & Giugliano, R. (2010) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944710368206 · Cited by 16

Treatment of the Dyslipidemia of Insulin Resistance

Smith, D. A. (2007) · Medical Clinics of North America · doi:10.1016/j.mcna.2007.06.008 · Cited by 14

Change in High-Density Lipoprotein Cholesterol and Incident Coronary Heart Disease in Apparently Healthy Male Physicians

Rahilly‐Tierney, C. R., Bowman, T. S., Djoussé, L., Sesso, H. D., & Gaziano, J. M. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.07.055 · Cited by 14

LIPIDS IN CHRONIC KIDNEY DISEASE

Lewis, D., Haynes, R., & Landray, M. (2010) · Journal of Renal Care · doi:10.1111/j.1755-6686.2010.00173.x · Cited by 14

Assessing outcomes of enhanced chronic disease care through patient education and a value-based formulary study (ACCESS)—study protocol for a 2×2 factorial randomized trial

Campbell, D. J. T., Tonelli, M. A., Hemmelgarn, B. R., Mitchell, C., Tsuyuki, R. T., Ivers, N. M., Campbell, T. S., Pannu, R., Verkerke, E., Klarenbach, S. W., et al. (2015) · Implementation Science · doi:10.1186/s13012-016-0491-6 · Cited by 14

Impact of Adding Eicosapentaenoic Acid to Statin Therapy on Plasma Pentraxin 3 Level in Patients with Stable Coronary Artery Disease: A 6-Month, Randomized Controlled Study

Tani, S., Nagao, K., Yagi, T., Atsumi, W., & Hirayama, A. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0195-y · Cited by 15

Intensive statin regimens for reducing risk of cardiovascular diseases among human immunodeficiency virus-infected population: A nation-wide longitudinal cohort study 2000–2011

Ou, H., Chang, K., Li, C., Yang, C., & Ko, N. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.12.050 · Cited by 14

Effectiveness of a combination of ezetimibe and statins in patients with acute coronary syndrome and multiple comorbidities: A 6-year population-based cohort study

Wu, F. L., Wang, J., Ho, W., Chou, C.-H., Wu, Y.-J., Choo, D., Wang, Y., Chen, P., Chien, K., & Lin, Z. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.02.006 · Cited by 14

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, Reality or Dream in Managing Patients with Cardiovascular Disease

Alkhalil, M. (2018) · Current Drug Metabolism · doi:10.2174/1389200219666180816141827 · Cited by 14

Leveraging structured and unstructured electronic health record data to detect reasons for suboptimal statin therapy use in patients with atherosclerotic cardiovascular disease

Gobbel, G. T., Matheny, M. E., Reeves, R. R., Akeroyd, J. M., Turchin, A., Ballantyne, C. M., Petersen, L. A., & Virani, S. S. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100300 · Cited by 14

Apolipoproteins and Diabetic Retinopathy

Chait, A., & Montes, V. N. (2011) · Diabetes Care · doi:10.2337/dc10-2119 · Cited by 14

Effects of Lipid‐Lowering Therapy on Reduction of Cardiovascular Events in Patients with End‐Stage Renal Disease Requiring Hemodialysis

Marrs, J. C., & Saseen, J. J. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.8.823 · Cited by 15

Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension

Tocci, G., Sciarretta, S., Facciolo, C., & Volpe, M. (2007) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.5.4.767 · Cited by 14

Unstable Angina and Non–ST Elevation Myocardial Infarction

Cannon, C. P., & Braunwald, E. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00056-1 · Cited by 16

Benefit of Combination Ezetimibe/Simvastatin Among High-Risk Populations: Lessons from the IMPROVE-IT Trial

Oliver, W., & Giugliano, R. P. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01084-4 · Cited by 13

Safety Profile of High-Dose Statin Therapy in Geriatric Patients with Stroke

Manocha, D., Bansal, N., Gumaste, P., & Brangman, S. A. (2013) · Southern Medical Journal · doi:10.1097/smj.0000000000000024 · Cited by 13

Statin Therapy as Primary Prevention in Exercising Adults: Best Evidence for Avoiding Myalgia

Bosomworth, N. J. (2016) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2016.06.160085 · Cited by 14

Intensive versus moderate atorvastatin therapy and one-year graft patency after CABG: Rationale and design of the ACTIVE (Aggressive Cholesterol Therapy to Inhibit Vein Graft Events) randomized controlled trial (NCT01528709)

Kulik, A., Abreu, A. M., Boronat, V., & Ruel, M. (2017) · Contemporary Clinical Trials · doi:10.1016/j.cct.2017.06.006 · Cited by 13

Prevalence, treatment, and control of severe hyperlipidemia

Gold, M. E., Nanna, M. G., Doerfler, S. M., Schibler, T., WOJDYLA, D. M., Peterson, E. D., & Návar, A. M. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100079 · Cited by 13

Trimerized apolipoprotein A-I (TripA) forms lipoproteins, activates lecithin:cholesterol acyltransferase, elicits lipid efflux, and is transported through aortic endothelial cells

Ohnsorg, P. M., Mary, J.-L., Rohrer, L., Pech, M., Fingerle, J., & von Eckardstein, A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.09.001 · Cited by 13

The changes in cardiovascular prevention practice between 1995 and 2012 in the Czech Republic. A comparison of EUROASPIRE I, II, III and IV study

Mayer, O., Bruthans, J., & Timoracká, K. (2014) · Cor et Vasa · doi:10.1016/j.crvasa.2014.01.008 · Cited by 13

Low‐Density Lipoprotein Reduction and Magnitude of Cardiovascular Risk Reduction

Rahilly‐Tierney, C. R., Lawler, E. V., Scranton, R. E., & Gaziano, J. M. (2009) · Preventive Cardiology · doi:10.1111/j.1751-7141.2008.00018.x · Cited by 13

Comparison of lipid control in patients with coronary versus peripheral artery disease following the first vascular intervention.

Pereg, D., Neuman, Y., Elis, A., Minha, S., Mosseri, M., Segev, D., Lishner, M., & Hermoni, D. (2012) · American Journal of Cardiology · doi:10.1016/j.amjcard.2012.06.030 · Cited by 18

Economic impacts attributable to the early clinical benefit of atorvastatin therapy – a US managed care perspective

Straka, R. J., Mamdani, M., Damen, J., Kuntze, C. E. E., Liu, L. Z., Botteman, M. F., & Koren, M. J. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x199808 · Cited by 13

Bergamot Polyphenols: Pleiotropic Players in the Treatment of Metabolic Syndrome

Walker, V. M. R. (2014) · Journal of Metabolic Syndrome · doi:10.4172/2167-0943.1000143 · Cited by 13

Geranylgeraniol prevents statin-induced skeletal muscle fatigue without causing adverse effects in cardiac or vascular smooth muscle performance

Irwin, J. C., Fenning, A. S., & Vella, R. K. (2019) · Translational research · doi:10.1016/j.trsl.2019.08.004 · Cited by 13

Lipid-Lowering Therapy in Patients 75 Years and Older: Clinical Priority or Superfluous Therapy?

Phan, B. A. P., & Bittner, V. (2014) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2014.03.005 · Cited by 13

Novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: a patent review

Pfefferkorn, J. A. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.547478 · Cited by 13

Lipoprotein and apolipoprotein ratios in the VYTAL trial of ezetimibe/simvastatin compared with atorvastatin in type 2 diabetes

Guyton, J. R., Goldberg, R. B., Mazzone, T., Weinstock, R. S., Polis, A. B., Rosenberg, E., & Tershakovec, A. M. (2008) · Journal of clinical lipidology · doi:10.1016/j.jacl.2007.12.004 · Cited by 13

A Systematic Review and Meta-Analysis of the Incidence and Risk Factors for Major Adverse Cardiovascular Events in Patients with Unrepaired Abdominal Aortic Aneurysms

Sharma, C., Singh, T. P., Thanigaimani, S., Nastasi, D. R., & Golledge, J. (2023) · Biomedicines · doi:10.3390/biomedicines11041178 · Cited by 12

Effect of Electronic Prescription on Attainment of Cholesterol Goals

Michelis, K. C., Hassouna, B., Owlia, M., Kelahan, L. C., Young, H. A., & Choi, B. G. (2011) · Clinical Cardiology · doi:10.1002/clc.20861 · Cited by 12

Rationale and Design of Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy with Pitavastatin in Coronary Artery Disease (REAL-CAD) Trial

Miyauchi, K., Kimura, T., Shimokawa, H., Daida, H., Iimuro, S., Iwata, H., Ozaki, Y., Sakuma, I., Nakagawa, Y., Hibi, K., et al. (2018) · International Heart Journal · doi:10.1536/ihj.17-557 · Cited by 12

Motivational interviewing to support LDL-C therapeutic goals and lipid-lowering therapy compliance in patients with acute coronary syndromes (IDEAL-LDL) study: rationale and design

Boulmpou, A., Κάρτας, Α., Farmakis, I. T., Zafeiropoulos, S., Nevras, V., Papadimitriou, I., Tampaki, A., Vlachou, A., Lillis, L., Koutsakis, A., et al. (2018) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2018.10.002 · Cited by 13

Cholesterol goal achievement and lipid-lowering therapy in patients with stable or acute coronary heart disease in Singapore: results from the Dyslipidemia International Study II

Poh, K. K., Ct, C., Tong, K., Tan, J., Lim, J., Yu, W., Horack, M., Vyas, A., Lautsch, D., Ambegaonkar, B. M., et al. (2019) · Singapore Medical Journal · doi:10.11622/smedj.2019021 · Cited by 12

Lowering LDL cholesterol with margarine containing plant stanol/sterol esters: Is it still relevant in 2011?

Doggrell, S. A. (2011) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2010.12.004 · Cited by 12

Refining Lipoprotein Assessment in Diabetes: Apolipoprotein B Makes Sense

Ganda, O. P. (2009) · Endocrine Practice · doi:10.4158/ep09064.rar · Cited by 12

Efficacy and Plasma Drug Concentrations With Nondaily Dosing of Rosuvastatin

Goldberg, A. S., DeGorter, M. K., Ban, M. R., Kim, R. B., & Hegele, R. A. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.12.015 · Cited by 12

Management of Lipids in Patients with Diabetes

Mbue, N. D., Mbue, J. E., & ANDERSON, J. A. (2017) · Nursing Clinics of North America · doi:10.1016/j.cnur.2017.07.009 · Cited by 12

Low-density lipoprotein cholesterol of less than 70 mg/dL is associated with fewer cardiovascular events in acute coronary syndrome patients: a real-life cohort in Thailand

Phrommintikul, A., Chinwong, D., Patumanond, J., Chinwong, S., Siriwattana, K., Gunaparn, S., & Hall, J. J. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s78745 · Cited by 12

Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA

Barrios, V., & Escobar, C. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.119 · Cited by 12

Ischemic stroke: A cardiovascular risk equivalent? Lessons learned from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial

FITCHETT, D. H., Goodman, S. G., & Langer, A. (2008) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(08)70669-x · Cited by 12

Safety Profile of Atorvastatin 80 mg: A Meta-Analysis of 17 Randomized Controlled Trials in 21,910 Participants

Li, H., Wang, C., Zhang, S., Sun, S., Li, R., Zou, M., & Cheng, G. (2016) · Drug Safety · doi:10.1007/s40264-016-0394-0 · Cited by 12

Intensive Statin Therapy After Stroke or Transient Ischemic Attack

Ovbiagele, B. I., & Saver, J. L. (2007) · Stroke · doi:10.1161/01.str.0000258216.83927.6a · Cited by 12

Impact of lipid levels and high‐intensity statins on vein graft patency after CABG: Midterm results of the ACTIVE trial

Kulik, A., Abreu, A. M., Boronat, V., & Ruel, M. (2020) · Journal of Cardiac Surgery · doi:10.1111/jocs.15014 · Cited by 11

Efficacy and Safety of Pitavastatin/Ezetimibe Fixed-Dose Combination vs. Pitavastatin: Phase III, Double-Blind, Randomized Controlled Trial

Tsujita, K., Yokote, K., Ako, J., Tanigawa, R., Tajima, S., & Suganami, H. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64006 · Cited by 12

Hyperlipidemia and Cardiovascular Disease in People with Type 1 Diabetes: Review of Current Guidelines and Evidence

Karmali, R., Sipko, J., Majid, M., & Bruemmer, D. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01866-x · Cited by 11

Doctors’ perceptions of the prognostic benefit of statins in patients who have had myocardial infarction

Sapre, N., Mann, S., & Elley, C. R. (2008) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2008.01729.x · Cited by 11

PCSK9 Inhibition: Current Concepts and Lessons from Human Genetics

Rodríguez, F., & Knowles, J. W. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0487-8 · Cited by 13

Emergent Biomarkers of Residual Cardiovascular Risk in Patients with Low HDL‐c and/or High Triglycerides and Average LDL‐c Concentrations: Focus on HDL Subpopulations, Oxidized LDL, Adiponectin, and Uric Acid

Mascarenhas‐Melo, F., Palavra, F., Marado, D., Sereno, J., Teixeira‐Lemos, E., Freitas, I., Isabel-Mendonça, M., Pinto, R. M. A., Teixeira, F. J., & Reis, F. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/387849 · Cited by 11

ACCF/AHA Practice Guideline 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

Hillis, L. D., Smith, P. K., Anderson, J. L., Bittl, J. A., Bridges, C. R., Byrne, J. G., Cigarroa, J. E., DiSesa, V. J., Hiratzka, L. F., Hutter, A. M., et al. (2011) · Cited by 11

Antithrombotic Drug Therapy in Cardiovascular Disease

Askari, A. T., & Lincoff, A. M. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-235-3 · Cited by 11

Statins and the cholesterol mortality paradox

Nunes, J. P. L. (2016) · Scottish Medical Journal · doi:10.1177/0036933016681913 · Cited by 11

Effect of Switching from Low-Dose Simvastatin to High-Dose Atorvastatin on Glucose Homeostasis and Cognitive Function in Type 2 Diabetes

Thongtang, N., Tangkittikasem, N., Samaithongcharoen, K., Piyapromdee, J., Srinonprasert, V., & Sriussadaporn, S. (2020) · Vascular Health and Risk Management · doi:10.2147/vhrm.s270751 · Cited by 11

Role of the Pharmacist

Bottorff, M. B. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.12part2.227s · Cited by 11

Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified by National Cholesterol Education Program Risk Category

Polis, A. B., Abate, N. I., Catapano, A. L., Ballantyne, C. M., Davidson, M. H., Smugar, S. S., & Tershakovec, A. M. (2009) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2009.0009 · Cited by 11

Mulling over the odds of CETP inhibition

von Eckardstein, A. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp394 · Cited by 11

Review: high dose statins reduce risk of non-fatal cardiovascular events more than standard dose statins

Newby, L. K. (2007) · BMJ Evidence-Based Medicine · doi:10.1136/ebm.12.2.42

The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials

Josan, K., Majumdar, S. R., & McAlister, F. A. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.070675 · Cited by 197

Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients

Mills, E. J., O’Regan, C., Eyawo, O., Wu, P., Mills, F. P., Berwanger, O., & Briel, M. (2017) · reroDoc Digital Library

Meta-analysis of the cardiovascular benefits of intensive lipid lowering with statins

Chan, D. K. Y., O’Rourke, F., Shen, Q. X., Mak, J. C. S., & Hung, W. T. (2010) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2010.01450.x · Cited by 26

Impact of statin dose on major cardiovascular events: A mixed treatment comparison meta-analysis involving more than 175,000 patients

Ribeiro, R. A., Ziegelmann, P. K., Duncan, B. B., Stella, S. F., Vieira, J. L. D. C., Restelatto, L. M. F., Moriguchi, E. H., & Polanczyk, C. A. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.10.128 · Cited by 34